U50,488, a highly selective kappa opioid: anticonvulsant profile in rats

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Epilepsy is a neurological disorder characterized by recurrent seizures.
• Current antiepileptic drugs have limitations, necessitating the development of novel therapeutic agents.
• Opioid receptors, particularly kappa opioid receptors, are implicated in seizure modulation.

Purpose of the Study:

• To investigate the anticonvulsant potential of U50,488, a selective kappa opioid agonist, in a rat model.
• To characterize the dose- and time-dependency of U50,488's anticonvulsant effects.
• To explore the involvement of opioid receptor subtypes in U50,488's anticonvulsant action.

Main Methods:

• Administration of U50,488 via subcutaneous (s.c.) or intracerebroventricular (i.c.v.) routes in rats.
• Evaluation of anticonvulsant activity against supramaximal electroshock seizures and flurothyl-induced convulsions.
• Dose-response studies to determine ED50 values and duration of action.
• Antagonism studies using naloxone to probe receptor involvement.

Main Results:

• U50,488 exhibited a dose- and time-dependent anticonvulsant effect in rats.
• The anticonvulsant action was specific to supramaximal electroshock seizures, not flurothyl-induced convulsions.
• Subcutaneous U50,488 had an ED50 of 8.6 mg/kg with a duration exceeding 8 hours.
• Intracerebroventricular U50,488 had an ED50 of 103.8 micrograms, lasting approximately 1 hour.
• High-dose naloxone partially antagonized the anticonvulsant effect, suggesting kappa receptor mediation.

Conclusions:

• U50,488 is an effective and long-acting anticonvulsant against specific seizure types in rats.
• The anticonvulsant effect appears to be mediated by non-mu (likely kappa) opioid receptors.
• This novel nonpeptide opioid may offer a new avenue for developing treatments for grand mal and partial epilepsies.